Coherus Biosciences Inc. (CHRS)
NASDAQ · Healthcare
Coherus Biosciences Inc. EBITDA 2012–2025
Coherus Biosciences Inc. annual/quarterly ebitda history and growth rate from 2012 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Coherus Biosciences Inc. ebitda for the quarter ending March 31, 2026 was -35.3 M, a 21.68% decrease year-over-year.
- Coherus Biosciences Inc. ebitda for the twelve months ending March 31, 2026 was -169.5 M, a 7.85% decrease year-over-year.
- Coherus Biosciences Inc. annual ebitda for 2025 was -179.8 M, a 9.20% decrease from 2024.
- Coherus Biosciences Inc. annual ebitda for 2024 was -198.1 M, a 0.97% decrease from 2023.
- Coherus Biosciences Inc. annual ebitda for 2023 was -200.0 M, a 21.04% decrease from 2022.
- Coherus Biosciences Inc. annual ebitda for 2022 was -253.3 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Coherus Biosciences Inc. EBITDA — FAQ
Coherus Biosciences Inc. (CHRS) ebitda over the last 14 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CHRS's ebitda history?
The chart and table above show Coherus Biosciences Inc.'s ebitda by year and by quarter, including the growth rate.